Company Update: Johnson & Johnson (NYSE:JNJ) – The Leukemia Race: Gilead Vs. Johnson & Johnson, Roche

[at Seeking Alpha] – Last November the FDA approved Imbruvica, a drug made by Pharmacyclics ( PCYC ) and Johnson and Johnson’s ( JNJ ) for the treatment of MCL (mantle-cell lymphoma) but . . . → Read More: Company Update: Johnson & Johnson (NYSE:JNJ) – The Leukemia Race: Gilead Vs. Johnson & Johnson, Roche Similar Articles: Company Update: General Motors Company (NYSE:GM) – Customers could win from GM-VW sales race Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – [video] Biogen CEO: More products, company is focused Company Update: Celgene Corporation (NASDAQ:CELG) – Celgene and Pharmacyclics Bring Big Change to Mantle Cell Lymphoma in 2013